British drugmaker GSK said on Wednesday it was "well positioned" to respond to any potential financial impact from ...

British drugmaker GSK said it was "well positioned" to respond to any potential impact from sector-specific tariffs if they ...

The American Association for Cancer Research’s annual conference continued Monday with Roche offering a postmortem for its ...

Going forward, PTS and Appspace are providing ongoing service and support, with a team ensuring the systems perform at peak ...

The report covers 40+ companies and 50+ pipeline drugs. Explore drug profiles from clinical to nonclinical stages, assessment by product type, and detailed pipeline development activities. Key players ...

Abnormal kinase signaling can promote other harmful traits, such as neuroinflammation and neuronal cell death. On the other ...

Numerous studies conducted by researchers at Dana-Farber Cancer Institute report progress for cancers including head and neck cancer, metastatic breast cancer and lung cancer.

A sign with the company logo sits outside of the headquarters campus of Eli Lilly and Company on March 17, 2024 in ...

Winners of the ADGHW Innovation Awards 2025 addressed prenatal gene editing, robotic organ transplantation, precision drug ...

BNP Paribas Exane analyst Peter Verdult initiated coverage of GSK (GSK) with a Neutral rating and $35.25 price target Discover outperforming stocks and invest smarter with Top Smart Score Stocks.

Hence, she liquidated all but a tiny percentage of her GSK holding, dramatically boosting her net gains. Today, we both own small legacy stakes in GSK, but nothing like the lump we once had.